info@p-95.com

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

LOGEX and P95 to jointly build the international infectious disease observatory ARWEN ID

Healthcare analytics provider LOGEX and P95, a company specialized in epidemiology of infectious diseases, have signed an agreement to jointly create an international infectious disease observatory. The goal of the observatory is to offer an international platform for research of infectious diseases like COVID-19, RSV, Influenza, Norovirus and other infections that may have a significant health impact in Europe. Additionally, the platform will be used for assessing the impact, effectiveness and safety of vaccines or other pharmaceutical health interventions.

The observatory will initially include 20 hospitals in five European countries. The first proof-of-concept studies will be presented at the end of 2023. The observatory’s name, ARWEN ID, is derived from the Actionable Real World Evidence Network (ARWEN) and its focus on infectious diseases (IDs).

Find us on LinkedIn to follow the progress of this new joint effort.

For more information on LOGEX, visit LOGEX.com

For more information on P95, visit p-95.com

For more information on ARWEN, visit arwen.eu 

P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

0 Comments

You May Also Like

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.